Galderma’s New IL‑17A & SIRT1 Drugs Show Early Promise Despite Market Slump
Galderma’s early‑stage IL‑17A and SIRT1 drugs show promise, but investors stay cautious as the Swiss market weighs regulatory milestones and pipeline risk.
5 minutes to read
